Samsung Biologics has agreed to acquire GlaxoSmithKline’s Human Genome Sciences and its two pharmaceutical manufacturing ...
LAVAL, QC / ACCESS Newswire / December 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") and its subsidiary 1261229 B.C. Ltd. (the "Issuer" and, together with the Company, ...
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 23, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential ...
The United States accounts for a significant share of the global remote patient monitoring (RPM) market. The U.S. RPM market ...
OverviewThe global NLP in healthcare & life sciences market is anticipated to expand at a CAGR of nearly 25% during the forecast period, fueled by widespread EHR adoption, rising interest in ...
Ondine and Mid Yorkshire Teaching NHS Trust shortlisted for Excellence in Healthcare Partnership Award for Reducing Surgical Site Infections with Nasal Photodisinfection Second national award ...
Dr. Martin discusses how counterfeit neurotoxins and non-medical providers can lead to preventable complications and long-term harm. MIAMI, FL / ACCESS Newswire / December 23, 2025 / A recent ...
OAKLAND, CA / ACCESS Newswire / December 23, 2025 / The Church of Ambrosia and Oakland Rapper Mistah F.A.B. expect a record turnout in today's toy giveaway for children and families.Community ...
Global Absorbable Sutures Market OverviewThe global absorbable sutures market is projected to grow at a steady rate of around 5% over the next five years, supported by the increasing number of ...
Expedited Development Enabled by RMAT and Breakthrough Therapy StatusClinical Trial Initiation in 2026, FDA Approval Target by 2030 LOS ANGELES, CA / ACCESS Newswire / December 23, 2025 / Nature Cell ...
IFAD and the GEF announce three climate-resilience investments in rural people in Eritrea, Kiribati and MalawiRome, 22 December 2025. The International Fund for Agricultural Development (IFAD), in ...
Incentive scheme for rare disease drug development vital for sector, says leading biotechSynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the ...